New Diagnostic Technology for Cervical Cancer

A new protein-based human papillomavirus (HPV) cervical cancer diagnostic technology is undergoing testing and validation studies.

HPV causes virtually all cervical cancers. Through a proprietary protein-based technology, a new assay under development looks at HPV in a fashion that identifies cervical cancer, its precursors, or the likelihood of its presence. This immunoassay includes antibodies especially associated with HPV-caused neoplasias or cancers that are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in HPV. The test is being developed by Grant Life Sciences, Inc. (Raleigh, NC, USA).

Through an agreement with Grant, Allogen Laboratories, a subsidiary of the Cleveland Clinic Foundation (OH, USA), will perform testing and validation studies on Grant's test. The test would be the first diagnostic to directly detect cervical cancer. Grant says the test has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors.

"We are very excited about this opportunity to participate in the validation process of this potentially very significant diagnostic test,” noted Dr. Daniel Cook, director of Allogen Laboratories. "It's a great opportunity to explore the potential of new technologies in order to overcome the limitations of current methodologies.”






Related Links:
Grant Life Sciences
Cleveland Clinic